China Seen Benefiting From U.S. FDA Ban On 30 Ranbaxy Drugs
This article was originally published in PharmAsia News
China could be the main beneficiary of the U.S. ban on 30 Ranbaxy Laboratories drugs, say analysts in China. One said Chinese drug makers are in line to take the market sector in the United States that Ranbaxy could lose by the ban. Pharmas in China have been increasing their own production, and the country's regulatory requirements are expected to help Chinese pharmaceuticals gain a share of India's U.S. market. Another notes China's leadership in making active pharmaceutical ingredients used by most drug makers. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.